Retrovirus & Opportunistic Infections Part II (cont.)
There were several important presentations at this meeting related to the pharmacokinetic interactions between drugs. One study assessed the interaction between lopinavir/ritonavir and tipranavir, two PIs that are often active in treatment-experienced subjects. They found that by increasing the dose of lopinavir/ritonavir to the equivalent to 4 capsules twice a day with an extra dose of ritonavir, or by giving extra doses of ritonavir with standard doses of lopinavir/ritonavir they were partly able to overcome some of the reduction in lopinavir levels seen when co-administered with tipranavir. Despite this, there was considerable variability in lopinavir levels and the authors recommended that if used together therapeutic drug monitoring should be considered.
Dr. Pham and colleagues at Johns Hopkins looked at the interaction between lopinavir/ritonavir and atazanavir. In this case they found with standard doses reasonably good levels of both drugs were maintained, although the clinical situation which these two drugs might be used in combination remains to be seen. Because there are many people who have extensive drug resistance and are looking at novel agents that they can use together, one study by Dr. Scholler from Tibotec, analyzed the drug-drug interaction between their new NNRTI TMC-125, with a recently approved PI called tipranavir that has been used for treatment-experienced patients. Unfortunately, they found that when these two drugs were used in combination there was a marked reduction in the TMC 125 levels, making this a nonviable option.
Finally, another pharmacokinetic study that may be relevant for the practitioner analyzed data from subjects taking both lopinavir/ritonavir and the lipid-lowering drug rosuvastatin. In this case lopinavir levels were unchanged but there was a 1.5 to 2-fold increase in rosuvastatin levels, the latter being based upon data from historical controls. Based upon these results the authors suggest that these drugs could be used together, although probably best to start with low dose rosuvastatin and titrate up based upon response to therapy.
There were several presentations looking at the potential utility of screening for STIs in asymptomatic individuals. The significance of this is that the presence of STIs is a marker for unsafe sexual activity and if active infection occurs or the STIs are transmitted it can be associated with morbidity as well as increased risk of HIV transmission. One study by Dr. Rieg and colleagues from Harbor-UCLA Medical Center screened 212 HIV-infected men who have sex with men followed in an urban clinic. Survey information was collected along with testing for syphilis as well as gonorrhea and chlamydia in urine as well as at the pharynx and the rectal sites. These investigators found that 13 percent of subjects tested positive for 35 STIs, with many identified at the rectal and pharyngeal mucosa, locations that are not routinely screened in clinical practice. Those with STIs were all treated and proven to be cured of this infection and then all enrolled subjects were tested again at 6 months. At the second visit many subjects from the cohort were found to be newly infected. The strongest predictor of being infected was having had at least two partners in the last six months. This kind of data will be important for ultimately defining the optimal strategies for screening at risk individuals for asymptomatic STIs.
Visit our HIV/AIDS center for the latest updates.
Last Editorial Review: 2/8/2006
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions